Jeffrey Weber, M.D., Ph.D. deputy director of NYU Langone Medical Center’s Laura and Isaac Perlmutter Cancer Center answers pressing questions from patients about cancer immunotherapy. For more, visit https://www.cancerresearch.org/patients/free-resources-support-answers/ask-a-scientist-video-series
Yes, someone with mild autoimmune disease should be able to receive most immunotherapies. Oncologists can work with a patient’s rheumatologist to customize a treatment plan for maximum benefit with limited adverse effects.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to harnessing our immune system’s power to control and potentially cure all cancers. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. Our Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. https://www.cancerresearch.org
This series is made possible with generous support from Regeneron.